Brokers Offer Predictions for Alkermes plc's Q1 2025 Earnings (NASDAQ:ALKS)

Alkermes plc (NASDAQ:ALKS - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Alkermes in a research note issued on Thursday, May 2nd. HC Wainwright analyst D. Tsao expects that the company will earn $0.43 per share for the quarter. HC Wainwright currently has a "Neutral" rating and a $35.00 target price on the stock. The consensus estimate for Alkermes' current full-year earnings is $2.39 per share. HC Wainwright also issued estimates for Alkermes' Q2 2025 earnings at $0.56 EPS, Q3 2025 earnings at $0.54 EPS and Q4 2025 earnings at $0.52 EPS.

Alkermes (NASDAQ:ALKS - Get Free Report) last issued its quarterly earnings results on Wednesday, May 1st. The company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.58 by ($0.15). The company had revenue of $350.37 million during the quarter, compared to analysts' expectations of $360.26 million. Alkermes had a return on equity of 20.31% and a net margin of 25.17%. The company's revenue for the quarter was up 21.8% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.10) EPS.

Several other research analysts have also weighed in on ALKS. UBS Group lowered Alkermes from a "neutral" rating to a "sell" rating and set a $25.00 price target on the stock. in a research report on Tuesday, February 20th. Jefferies Financial Group boosted their target price on Alkermes from $42.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday, April 9th. Robert W. Baird initiated coverage on Alkermes in a research note on Tuesday, March 19th. They set an "outperform" rating and a $37.00 price target for the company. TheStreet raised Alkermes from a "c+" rating to a "b" rating in a research note on Thursday, February 15th. Finally, StockNews.com cut shares of Alkermes from a "buy" rating to a "hold" rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average price target of $35.38.

Alkermes Trading Up 0.2 %

NASDAQ ALKS traded up $0.05 on Monday, hitting $24.10. 1,591,911 shares of the stock were exchanged, compared to its average volume of 1,890,784. The company's 50-day moving average price is $26.61 and its two-hundred day moving average price is $26.71. The company has a market capitalization of $4.08 billion, a price-to-earnings ratio of 9.53, a P/E/G ratio of 0.64 and a beta of 0.61. Alkermes has a 52-week low of $22.01 and a 52-week high of $33.71. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.20 and a quick ratio of 2.77.

Alkermes declared that its Board of Directors has initiated a share buyback plan on Thursday, February 15th that authorizes the company to buyback $400.00 million in shares. This buyback authorization authorizes the company to repurchase up to 8.2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company's board believes its shares are undervalued.

Insider Transactions at Alkermes

In related news, SVP Christian Todd Nichols sold 10,417 shares of Alkermes stock in a transaction dated Monday, March 18th. The stock was sold at an average price of $28.10, for a total transaction of $292,717.70. Following the sale, the senior vice president now directly owns 65,911 shares of the company's stock, valued at $1,852,099.10. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 4.89% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Handelsbanken Fonder AB lifted its holdings in shares of Alkermes by 521.3% during the 4th quarter. Handelsbanken Fonder AB now owns 175,200 shares of the company's stock worth $4,860,000 after acquiring an additional 147,000 shares during the period. Allspring Global Investments Holdings LLC grew its stake in shares of Alkermes by 81.4% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 377,489 shares of the company's stock valued at $10,472,000 after purchasing an additional 169,385 shares during the period. Rafferty Asset Management LLC lifted its position in shares of Alkermes by 15.7% during the 3rd quarter. Rafferty Asset Management LLC now owns 308,545 shares of the company's stock worth $8,642,000 after buying an additional 41,753 shares during the period. Jennison Associates LLC boosted its stake in Alkermes by 33.4% in the 4th quarter. Jennison Associates LLC now owns 36,335 shares of the company's stock valued at $1,008,000 after buying an additional 9,106 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in Alkermes by 10.0% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,461,246 shares of the company's stock valued at $40,930,000 after acquiring an additional 133,357 shares during the period. 95.21% of the stock is owned by institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.